| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP and COO
1 company
Stefani Wolff last filed a Form 4 in April 2023, as EVP and COO at NRIX. Stefani Wolff's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Stefani Wolff's trades have earned a middling insider score of 65/100 across 5 rated trades. Over a 12-month horizon, 80.0% of those trades were profitable, with an average 12-month return of +25.4%.
At the last filing, the largest reported position was 6,113 shares of NRIX. The NRIX filings lean toward selling, a net 1,802 shares.
Stefani Wolff has 8 Form 4 filings on record from January 2022 to April 2023, all as EVP and COO at Nurix Therapeutics (NRIX), 2022–2023.
The 15 reported transactions were 5 option exercises, 5 open-market sales and 5 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 5 sales worth about $22K.
The largest open-market sale was 356 shares of NRIX at an average $15.67 on August 1, 2022, about $6K. Twelve months later NRIX was down 38%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2023 | NRIX Nurix Therapeutics, Inc. | EVP and COO | Sale+OE | 342 | $9.88 | $3,377.69 | -5.3% | -1.9% | +21.4% | |
| Jan 30, 2023 | NRIX Nurix Therapeutics, Inc. | EVP and COO | Sale+OE | 424 | $11.78 | $4,994.55 | -9.7% | -16.6% | -32.7% | |
| Oct 31, 2022 | NRIX Nurix Therapeutics, Inc. | EVP and COO | Sale+OE | 350 | $12.88 | $4,508.18 | -9.3% | -6.8% | -56.1% | |
| Aug 1, 2022 | NRIX Nurix Therapeutics, Inc. | EVP and COO | Sale+OE | 356 | $15.67 | $5,578.52 | -22.3% | -17.4% | -38.4% | |
| May 2, 2022 | NRIX Nurix Therapeutics, Inc. | EVP and COO | Sale+OE | 330 | $11.75 | $3,877.50 | -34.3% | +28.8% | -21.4% |